Shionogi & Co Ltd
TSE:4507
Shionogi & Co Ltd
Gross Profit
Shionogi & Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Gross Profit
¥370.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
7%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Gross Profit
¥3T
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Gross Profit
¥1.4T
|
CAGR 3-Years
26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Gross Profit
¥1.7T
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Gross Profit
¥831.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Gross Profit
¥1.5T
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
Shionogi & Co Ltd
Glance View
In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.
See Also
What is Shionogi & Co Ltd's Gross Profit?
Gross Profit
370.6B
JPY
Based on the financial report for Dec 31, 2024, Shionogi & Co Ltd's Gross Profit amounts to 370.6B JPY.
What is Shionogi & Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
7%
Over the last year, the Gross Profit growth was 2%. The average annual Gross Profit growth rates for Shionogi & Co Ltd have been 16% over the past three years , -7% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet